REASON: TKI sensitive EGFR mutation status and associated characteristics of advanced NSCLC patients – Results from a German registry. Thomas, M., Eberhardt, W., Graf von der Schluenburg, J., Dietel, M., Schirmacher, P., Gutendirf, B., Schaller, F., Schütte, W., 2011. Onkologie 34 (suppl 6)(V451), 124. Abstract EGFR Mutation Status in NSCLC Patients Stage IIIB/IV in Germany – Initial Results from a German Registry. Thomas, M., Eberhardt, W., Graf von der Schulenburg, J.-M., Dietel, M., Schirmacher, P., Gutendorf, B., Zirrgiebel, U., Schütte, W., 2011. EMCC / ESMO, European Multidisciplinary… Weiterlesen Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. van de Velde, C.J.., Rea, D., Seynaeve, C., Putter, H., Hasenburg, A., Vannetzel, J.M., Paridaens, R., Markopoulos, C., Hozumi, Y., Hille, E., others, 2011. Lancet… Weiterlesen